サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1539651

慢性特発性蕁麻疹の世界市場レポート 2024年

Chronic Spontaneous Urticaria Global Market Report 2024

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
慢性特発性蕁麻疹の世界市場レポート 2024年
出版日: 2024年08月21日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

慢性特発性蕁麻疹市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR8.4％で28億4,000万米ドルに成長します。予測期間における成長の要因としては、慢性特発性蕁麻疹（CSU）の診断症例数の増加、患者層の拡大、ヘルスケアインフラの開拓、患者中心のケアモデルを推進する規制環境の支援、新興市場の経済成長などが挙げられます。この期間に予想される主な動向には、技術革新、生物学的療法の進歩、個別化医療アプローチ、遠隔医療とデジタルヘルスソリューションの統合、AIと機械学習を活用した診断ツールの進歩、医薬品の承認・上市の増加などがあります。

アルコール消費量の増加が予想されることから、慢性特発性蕁麻疹市場の今後の成長が期待されます。アルコール消費の増加要因には、社会規範、ストレス、広告、手頃な価格、入手可能性などがあります。個人によっては、アルコールの摂取が慢性特発性蕁麻疹の症状を悪化させ、じんましんや腫れのエピソードの増大につながることがあります。例えば、rehabs.UKが2024年2月に報告したところによると、英国では男性の55％、女性の41％が毎週アルコールを摂取しており、男性の8％、女性の5％がほぼ毎日のアルコール摂取を報告しています。2021年から2022年にかけて、アルコールのみに起因する入院患者数は342,795人で、人口10万人当たりの入院患者数は626人でした。したがって、アルコール消費の増加は慢性特発性蕁麻疹市場の成長の原動力となっています。

慢性特発性蕁麻疹市場の大手企業は、治療効果を高め、投与回数を減らすために、先進的な次世代モノクローナル抗免疫グロブリンE（IgE）抗体の開発に注力しています。これらの抗体は、慢性特発性蕁麻疹のような疾患の治療成績を改善し、投与間隔を延長するように設計されています。例えば、2021年1月、スイスに本社を置く製薬会社であるノバルティスAGは、H1-抗ヒスタミン薬による治療で十分な効果が得られない患者における慢性特発性蕁麻疹の治療薬として、リゲリズマブ（QGE031）のブレークスルーセラピー指定によるFDA承認を取得しました。リゲリズマブは慢性特発性蕁麻疹の治療において重要な進歩です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の市場規模と成長

  • 世界の慢性特発性蕁麻疹市場：促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の慢性特発性蕁麻疹市場の実績：規模と成長, 2018-2023
  • 世界の慢性特発性蕁麻疹市場の予測：規模と成長, 2023-2028, 2033年

第6章 市場セグメンテーション

  • 世界の慢性特発性蕁麻疹市場：治療別、実績と予測, 2018-2023, 2023-2028年, 2033年
  • 薬物療法
  • 光線療法
  • その他の治療法
  • 世界の慢性特発性蕁麻疹市場：投与経路別、実績と予測, 2018-2023, 2023-2028年, 2033年
  • 経口
  • 外用
  • 非経口
  • その他の投与経路
  • 世界の慢性特発性蕁麻疹市場：診断別、実績と予測, 2018-2023, 2023-2028年, 2033年
  • 身体検査
  • 血液検査
  • アレルギー検査
  • その他の診断
  • 世界の慢性特発性蕁麻疹市場：エンドユーザー別、実績と予測, 2018-2023, 2023-2028年, 2033年
  • 病院
  • 専門クリニック
  • ホームケア
  • その他のエンドユーザー

第7章 地域別・国別分析

  • 世界の慢性特発性蕁麻疹市場：地域別、実績と予測, 2018-2023, 2023-2028年, 2033年
  • 世界の慢性特発性蕁麻疹市場：国別、実績と予測, 2018-2023, 2023-2028年, 2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 慢性特発性蕁麻疹市場：競合情勢
  • 慢性特発性蕁麻疹市場：企業プロファイル
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co. Inc.
    • AbbVie Inc.
    • Bayer AG
    • Sanofi SA

第31章 その他の大手企業と革新的企業

  • AstraZeneca plc
  • Novartis AG
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Genentech Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Hikma Pharmaceuticals plc
  • Celltrion Inc.
  • Allakos Inc.
  • United BioPharma Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと潜在的な分析

第36章 付録

目次
Product Code: r19090

Chronic spontaneous urticaria (CSU) is a skin condition characterized by recurrent hives (raised, red, itchy welts) and angioedema (swelling) persisting for more than six weeks, without a clear external trigger. The exact cause of CSU is often unknown but may involve an autoimmune mechanism where the body's immune system erroneously targets healthy skin cells. Treatment primarily aims at managing symptoms, typically starting with antihistamines and, in more severe cases, other medications such as biologics.

The main treatments for chronic spontaneous urticaria include medication, phototherapy, and other interventions. Medication for CSU usually begins with antihistamines as the first-line approach, with options varying from non-sedating to sedating types based on the severity of symptoms and individual patient response. These medications can be administered orally, topically, parenterally, or through other routes. Diagnosis involves physical examination, blood tests, and allergy testing, and the treatments are utilized across various settings including hospitals, specialty clinics, home care settings, among others.

The chronic spontaneous urticaria research report is one of a series of new reports from The Business Research Company that provides chronic spontaneous urticaria market statistics, including the chronic spontaneous urticaria industry's global market size, regional shares, competitors with a chronic spontaneous urticaria market share, detailed chronic spontaneous urticaria market segments, market trends and opportunities, and any further data you may need to thrive in the chronic spontaneous urticaria industry. This chronic spontaneous urticaria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic spontaneous urticaria market size has grown strongly in recent years. It will grow from $1.90 billion in 2023 to $2.06 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The growth observed in the historic period can be attributed to several factors, advancements in diagnostic tools, increased awareness among healthcare professionals, support from patient advocacy groups, ongoing studies and clinical trials investigating new therapies, and rising healthcare expenditure.

The chronic spontaneous urticaria market size is expected to see strong growth in the next few years. It will grow to $2.84 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. In the forecast period, growth can be attributed to several factors, an increasing number of diagnosed cases of chronic spontaneous urticaria (CSU), expansion of the patient pool, development of healthcare infrastructure, supportive regulatory environments promoting patient-centric care models, and economic growth in emerging markets. Major trends anticipated during this period include technological innovations, advancements in biological therapies, personalized medicine approaches, the integration of telemedicine and digital health solutions, advancements in diagnostic tools leveraging AI and machine learning, and a rise in drug approvals and launches.

The anticipated rise in alcohol consumption is expected to drive growth in the chronic spontaneous urticaria market moving forward. Factors contributing to increased alcohol consumption include social norms, stress, advertising, affordability, and availability. For some individuals, alcohol consumption can exacerbate symptoms of chronic spontaneous urticaria, leading to heightened episodes of hives and swelling. For example, rehabs.UK reported in February 2024 that 55% of men and 41% of women in the UK consume alcohol weekly, with 8% of men and 5% of women reporting near-daily alcohol consumption. Between 2021 and 2022, there were 342,795 hospital admissions attributed solely to alcohol, resulting in a rate of 626 admissions per 100,000 people. Therefore, the increasing consumption of alcohol is a driving force behind the growth of the chronic spontaneous urticaria market.

Leading companies in the chronic spontaneous urticaria market are focusing on developing advanced next-generation monoclonal anti-immunoglobulin E (IgE) antibodies to enhance treatment efficacy and reduce dosing frequency. These antibodies are designed to improve treatment outcomes and prolong dosing intervals for conditions such as chronic spontaneous urticaria. For instance, in January 2021, Novartis AG, a pharmaceutical company based in Switzerland, received FDA approval for ligelizumab (QGE031) with Breakthrough Therapy designation for treating chronic spontaneous urticaria in patients who do not adequately respond to H1-antihistamine treatment. Ligelizumab represents a significant advancement in the treatment of chronic spontaneous urticaria.

In March 2022, Novan Inc., a specialty dermatology company in the US, acquired EPI Health LLC to strengthen its commercial infrastructure in preparation for potential FDA approval of its lead product candidate, SB206 (berdazimer gel 10.3%), for molluscum contagiosum treatment. EPI Health LLC is known for providing Xyzal (levocetirizine) for managing uncomplicated skin manifestations.

Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

North America was the largest region in the chronic spontaneous urticaria market in 2023. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chronic spontaneous urticaria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic spontaneous urticaria market consists of revenues earned by entities by providing services such as diagnostic services and medical consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic spontaneous urticaria market also includes sales of antihistamines, corticosteroids, and cyclosporine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Spontaneous Urticaria Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic spontaneous urticaria market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic spontaneous urticaria ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic spontaneous urticaria market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Treatment: Medication; Phototherapy; Other Treatments
  • 2) By Route Of Administration: Oral; Topical; Parenteral; Other Routes Of Administration
  • 3) By Diagnosis: Physical Examination; Blood Test; Allergy Test; Other Diagnosis
  • 4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
  • Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Sanofi SA
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chronic Spontaneous Urticaria Market Characteristics

3. Chronic Spontaneous Urticaria Market Trends And Strategies

4. Chronic Spontaneous Urticaria Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Chronic Spontaneous Urticaria Market Size and Growth

  • 5.1. Global Chronic Spontaneous Urticaria Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Chronic Spontaneous Urticaria Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Chronic Spontaneous Urticaria Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Chronic Spontaneous Urticaria Market Segmentation

  • 6.1. Global Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Medication
  • Phototherapy
  • Other Treatments
  • 6.2. Global Chronic Spontaneous Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Topical
  • Parenteral
  • Other Administrations
  • 6.3. Global Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Physical Examination
  • Blood Test
  • Allergy Test
  • Other Diagnosis
  • 6.4. Global Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Homecare
  • Other End-Users

7. Chronic Spontaneous Urticaria Market Regional And Country Analysis

  • 7.1. Global Chronic Spontaneous Urticaria Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Chronic Spontaneous Urticaria Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Chronic Spontaneous Urticaria Market

  • 8.1. Asia-Pacific Chronic Spontaneous Urticaria Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Chronic Spontaneous Urticaria Market

  • 9.1. China Chronic Spontaneous Urticaria Market Overview
  • 9.2. China Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Chronic Spontaneous Urticaria Market

  • 10.1. India Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Chronic Spontaneous Urticaria Market

  • 11.1. Japan Chronic Spontaneous Urticaria Market Overview
  • 11.2. Japan Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Chronic Spontaneous Urticaria Market

  • 12.1. Australia Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Chronic Spontaneous Urticaria Market

  • 13.1. Indonesia Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Chronic Spontaneous Urticaria Market

  • 14.1. South Korea Chronic Spontaneous Urticaria Market Overview
  • 14.2. South Korea Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Chronic Spontaneous Urticaria Market

  • 15.1. Western Europe Chronic Spontaneous Urticaria Market Overview
  • 15.2. Western Europe Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Chronic Spontaneous Urticaria Market

  • 16.1. UK Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Chronic Spontaneous Urticaria Market

  • 17.1. Germany Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Chronic Spontaneous Urticaria Market

  • 18.1. France Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Chronic Spontaneous Urticaria Market

  • 19.1. Italy Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Chronic Spontaneous Urticaria Market

  • 20.1. Spain Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Chronic Spontaneous Urticaria Market

  • 21.1. Eastern Europe Chronic Spontaneous Urticaria Market Overview
  • 21.2. Eastern Europe Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Chronic Spontaneous Urticaria Market

  • 22.1. Russia Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Chronic Spontaneous Urticaria Market

  • 23.1. North America Chronic Spontaneous Urticaria Market Overview
  • 23.2. North America Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Chronic Spontaneous Urticaria Market

  • 24.1. USA Chronic Spontaneous Urticaria Market Overview
  • 24.2. USA Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Chronic Spontaneous Urticaria Market

  • 25.1. Canada Chronic Spontaneous Urticaria Market Overview
  • 25.2. Canada Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Chronic Spontaneous Urticaria Market

  • 26.1. South America Chronic Spontaneous Urticaria Market Overview
  • 26.2. South America Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Chronic Spontaneous Urticaria Market

  • 27.1. Brazil Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Chronic Spontaneous Urticaria Market

  • 28.1. Middle East Chronic Spontaneous Urticaria Market Overview
  • 28.2. Middle East Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Chronic Spontaneous Urticaria Market

  • 29.1. Africa Chronic Spontaneous Urticaria Market Overview
  • 29.2. Africa Chronic Spontaneous Urticaria Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Chronic Spontaneous Urticaria Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Chronic Spontaneous Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Chronic Spontaneous Urticaria Market Competitive Landscape And Company Profiles

  • 30.1. Chronic Spontaneous Urticaria Market Competitive Landscape
  • 30.2. Chronic Spontaneous Urticaria Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Merck & Co. Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. AbbVie Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Bayer AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Sanofi SA
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Chronic Spontaneous Urticaria Market Other Major And Innovative Companies

  • 31.1. AstraZeneca plc
  • 31.2. Novartis AG
  • 31.3. GlaxoSmithKline plc
  • 31.4. Eli Lilly and Company
  • 31.5. Amgen Inc.
  • 31.6. Teva Pharmaceutical Industries Ltd.
  • 31.7. Sun Pharmaceutical Industries Ltd.
  • 31.8. Aurobindo Pharma Limited
  • 31.9. Cipla Limited
  • 31.10. Genentech Inc.
  • 31.11. Dr. Reddy's Laboratories Ltd.
  • 31.12. Hikma Pharmaceuticals plc
  • 31.13. Celltrion Inc.
  • 31.14. Allakos Inc.
  • 31.15. United BioPharma Inc.

32. Global Chronic Spontaneous Urticaria Market Competitive Benchmarking

33. Global Chronic Spontaneous Urticaria Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Chronic Spontaneous Urticaria Market

35. Chronic Spontaneous Urticaria Market Future Outlook and Potential Analysis

  • 35.1 Chronic Spontaneous Urticaria Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Chronic Spontaneous Urticaria Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Chronic Spontaneous Urticaria Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer